Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO2020163866 - COMPOSITIONS COMPRENANT DES CANNABINOÏDES ET LEURS PROCÉDÉS D'UTILISATION

Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

[ EN ]

CLAIMS

What is claimed is:

1. A method of reducing acute migraine pain, photophobia, phonophobia, and/or nausea in a subject, the method comprising administering a pharmaceutically effective amount of at least one minor cannabinoid alone or in combination with THC, CBD, or both, such that at least one biomarker of central and peripheral sensitization is modulated and migraine pain, photophobia, phonophobia, and/or nausea is reduced in the subject.

2. A method of reducing migraine frequency in a subject, the method comprising administering a pharmaceutically effective amount of at least one minor cannabinoid alone or in combination with THC, CBD, or both, such that at least one biomarker of central and peripheral sensitization is modulated and migraine frequency is reduced in the subject.

3. The method of claim 2, wherein the subject has chronic migraines.

4. The method of claim 2, wherein the subject suffers from high frequency migraine.

5. A method of reducing fibromyalgia pain in a subject, the method comprising

administering a pharmaceutically effective amount of at least one minor cannabinoid alone or in combination with THC, CBD, or both, such that at least one biomarker of central and peripheral sensitization is modulated and

fibromyalgia pain is reduced in the subject.

6. A pharmaceutical composition comprising at least one isolated minor

cannabinoid and THC, wherein the ratio of isolated minor cannabinoid(s) to THC is selected to maximize the modulation of at least one biomarker of central and peripheral sensitization.

7. The composition of claim 6, wherein the composition further comprises CBD.

8. The composition of claim 6, wherein the composition further comprises a terpenoid.

9. The composition of claim 6, wherein the composition further comprises an

additional analgesic agent.

10. A pharmaceutical composition comprising at least one isolated minor

cannabinoid and CBD, wherein the ratio of isolated minor cannabinoid(s) to CBD is selected to maximize the modulation of at least one biomarker of central and peripheral sensitization.

11. The composition of claim 10, wherein the composition further comprises THC.

12. The composition of claim 10, wherein the composition further comprises a

terpenoid.

13. The composition of claim 10, wherein the composition further comprises an

additional analgesic agent.

14. The composition of any of claims 6-13 wherein the biomarker is selected from the group consisting of NMDA, glutamate, CGRP, FAAH, Substance P, 5-HT, NO, GABA, NGF, serotonin, dopamine, AEA, 2-AG.

15. The composition of any of claims 6-13 wherein the cannabinoid is selected from the group consisting of CBG, CBGA, CBN, CBNA, THCV, THCA, CBC, CBCA, CBDV, and D8-THC.

16. The composition of any of claims 6-13, wherein the composition comprises at least one cannabinoid is selected from the group consisting of CBG, CBGA,

CBN, CBNA, THCV, THCA, CBC, CBCA, CBDV, and D8-THC; THC; and CBD.

17. The method of any of claims 1 -6, wherein the biomarker is selected from the group consisting of NMDA, glutamate, CGRP, FAAH, Substance P, 5-HT, NO, GABA, NGF, serotonin, dopamine, AEA, 2-AG.

18. The method of any of claims 1 -6, wherein the cannabinoid is selected from the group consisting of CBG, CBGA, CBN, CBNA, THCV, THCA, CBC, CBCA, CBDV, and D8-THC.

19. The method of any of claims 1 -6, wherein the at least one cannabinoid is

selected from the group consisting of CBG, CBGA, CBN, CBNA, TFICV, TFICA, CBC, CBCA, CBDV, and D8-TFIC; and the subject is further administered TFIC and CBD.

20. A method of reducing acute migraine pain in a subject, the method comprising administering a pharmaceutically effective amount of TFIC and CBD such that at least one biomarker of central and peripheral sensitization is modulated and migraine pain is reduced in the subject, while reducing undesired side effects or risk factors of TFIC.

21.A method of reducing migraine frequency in a subject, the method comprising administering a pharmaceutically effective amount of TFIC and CBD, such that at least one biomarker of central and peripheral sensitization is modulated and migraine frequency is reduced in the subject, while reducing undesired side effects or risk factors of TFIC.

22. The method of claim 21 , wherein the subject has chronic migraines.

23. The method of claim 21 , wherein the subject suffers from high frequency

migraine.

24. A method of reducing fibromyalgia pain in a subject, the method comprising

administering a pharmaceutically effective amount of TFIC and CBD, such that at least one biomarker of central and peripheral sensitization is modulated and fibromyalgia pain is reduced in the subject, while reducing undesired side effects or risk factors of THC.

25. A pharmaceutical composition comprising THC and CBD, wherein the ratio of THC to CBD is selected to maximize the modulation of at least one biomarker of central and peripheral sensitization while reducing undesired side effects or risk factors of THC.

26. The composition of claim 25, wherein the composition further comprises a minor cannabinoid.

27. The composition of claim 25, wherein the composition further comprises a

terpenoid.

28. The composition of claim 25, wherein the composition further comprises an

additional analgesic agent.

29. The composition of any of claims 25-28 wherein the biomarker is selected from the group consisting of NMDA, glutamate, or CGRP.

30. The composition of claim 26, wherein the minor cannabinoid is selected from the group consisting of CBG, CBGA, CBN, CBNA, THCV, THCA, CBC, CBCA, CBDV, and D8-THC.

31. The method of any of claims 20-24, wherein the composition further comprises a minor cannabinoid selected from the group consisting of CBG, CBGA, CBN, CBNA, THCV, THCA, CBC, CBCA, CBDV, and D8-THC.